Logo Prima Biomed

Financial Information

ASX Filing

Date Price sens. Headline pages PDF
16/03/2017 Change of Director's Interest Notice - Marc Voigt 4
16/03/2017 Appendix 3B & Cleansing Notice 14
15/03/2017 ! PRR completes recruitment for 2nd patient cohort 2
10/03/2017 ! S&P DJ Indices Announces March Quarterly Rebalance 9
07/03/2017 Investor Update 4
01/03/2017 ! US patent granted for IMP321 2
24/02/2017 ! Half Yearly Report and Accounts 26
13/02/2017 ! French Research Tax Credit Payment Received 2
23/01/2017 Presentation at 2nd Annual Cancer Immunotherapy Conference 2
20/01/2017 PRR commences randomised phase IIb clinical trial 2
18/01/2017 Prima BioMed To Maintain NASDAQ Listing 1
12/01/2017 ! Prima commences recruitment for 2nd cohort of melanoma trial 2
06/01/2017 Prima January 2017 Corporate Presentation 36
06/01/2017 ! Appendix 4C - quarterly 5
05/01/2017 ! Prima BioMed enters new Material Transfer Agreement with Cytlimic 2
03/01/2017 ! Prima announces new LAG-3 agonist antibody product candidate 2
22/12/2016 ! Prima announces AIPAC clinical trial data 2
20/12/2016 ! Prima receives UK approval for AIPAC study 2
19/12/2016 ADR Ratio Change 2
06/12/2016 Change of Director's Interest Notice 3
06/12/2016 Appendix 3B 14
01/12/2016 Appendix 3B 13
25/11/2016 Results of Meeting 1
25/11/2016 2016 AGM CEO Presentation 27
25/11/2016 2016 AGM Address to Shareholders 3
23/11/2016 ! Wuxi & Prima sign MOU for strategic partnership 2
11/11/2016 Investor Update 6
11/11/2016 Presentation slides for Society for Immunotherapy of Cancer 5
25/10/2016 Notice of Annual General Meeting/Proxy Form 17
19/10/2016 ! Appendix 4C - quarterly 5
13/10/2016 Prima to present at SITC 2016 1
05/10/2016 Abstracts accepted for poster presentation at ESMO 2
04/10/2016 Change of Director's Interest Notice 3
04/10/2016 Appendix 3B & Cleansing Notice 14
04/10/2016 Annual Report filed on Form 20-F with SEC 131
28/09/2016 Appendix 4G 31
28/09/2016 Annual Report to shareholders 88
02/09/2016 Appendix 3B and Cleansing Notice 15
31/08/2016 ! Appendix 4E & 2016 Full Year Statutory Accounts 76
25/08/2016 ! European Patent Grants for IMP731 Antibody 2
18/08/2016 ! Operational Update 2
10/08/2016 Prima Biomed Receives NASDAQ Notice of Bid Price Deficiency 2
27/07/2016 ! Appendix 4C - quarterly 5
12/07/2016 ! PRR Collaborates In New Clinical Trial For Imp321 2
22/06/2016 ! First Data From Phase IIb Clinical Trial of Imp321 3
07/06/2016 Prima BioMed To Maintain NASDAQ Listing 1
30/05/2016 ! Prima BioMed Files U.S Shelf Registration Statement 83
12/05/2016 Investor Update 6
12/05/2016 ! PRR Enters Agreement with Sydys to Advance CVac Program 3
02/05/2016 Japanese Patent Grants For IMP321 In Cancer 2
21/04/2016 ! Response to ASX Price Query 4
08/04/2016 ! Appendix 4C - quarterly March 2016 5
15/03/2016 IMP321 data published in Clinical Cancer Research Journal 2
11/03/2016 ! S&P DJ Indices Announces March Quarterly Review 9
08/03/2016 Appointment of Joint Company Secretary 1
07/03/2016 Appendix 3B 13
04/03/2016 Prima receives NASDAQ deficiency notice 2
02/03/2016 ! First pateint dosed in AIPAC 3
29/02/2016 ! Half Yearly Report and Accounts 27
11/02/2016 Prima Newsletter 6
28/01/2016 ! US patent granted for IMP731 antibody 2
27/01/2016 ! Prima initiates Phase I melanoma study in Australia 3
08/01/2016 ! Response to ASX Price Query 4
07/01/2016 ! Appendix 4C - quarterly 5
29/12/2015 Appendix 3B 13
22/12/2015 ! Prima initiates phase IIb study in metastatic breast cancer 4
11/12/2015 ! Prima BioMed progresses Japanese Collaboration 3
26/11/2015 ! $420k R&D Tax Incentive Refund Received 1
25/11/2015 Results of Meeting 2
23/11/2015 Prima Newsletter 8
18/11/2015 ! Prima unveils Phase I combination study of IMP321 3
05/11/2015 Prima to present at Immune Checkpoint Inhibitor meeting 2
02/11/2015 Annual Report filed on Form 20-F with SEC 135
30/10/2015 Prima announces A$2m investment from institutional investor 14
30/10/2015 ! Prima announces A$2m investment from institutional investor 1
27/10/2015 ! Belgian regulatory approval received for AIPAC trial 3
22/10/2015 Appendix 4G 14
22/10/2015 Annual Report to Shareholders 62
22/10/2015 Notice of Annual General Meeting/Proxy Form 24
19/10/2015 Change of Address 1
14/10/2015 Information Required Under Listing Rule 3.10.5A 1
13/10/2015 ! Prima announces A$1.55m investment from Nyenburg 2
13/10/2015 Cleansing Notice & Appendix 3B 14
09/10/2015 Prima receives grant from the Saxony Development Bank 1
08/10/2015 Appendix 4C - quarterly 5
02/10/2015 Change of Director's Interest Notice 4
02/10/2015 Change of Director's Interest Notice 3
01/10/2015 Appendix 3B & Cleansing Notice 15
25/09/2015 Prima to present at Leerink Partners Rare Disease Roundtable 1
03/09/2015 ! Response to ASX Price Query 1
28/08/2015 Prima to present at Rodman & Renshaw Conference 2
28/08/2015 ! Appendix 4E & 2015 Full Year Statutory Accounts 92
14/08/2015 ! Milestone payment to be received from Novartis 2
05/08/2015 Change of Director's Interest Notice 4
05/08/2015 Appendix 3B 15
04/08/2015 Cleansing Notice 1
04/08/2015 Section 708A(12C)(e) Cleansing Notice 14
04/08/2015 Appendix 3B 14
04/08/2015 ! Warrants Prospectus 27
04/08/2015 ! Termination of Bergen Investment Facility 2
03/08/2015 Change of Director's Interest Notice 2
03/08/2015 Change of Director's Interest Notice 2
31/07/2015 Results of Meeting 3
31/07/2015 2015 EGM CEO's Presentation 16
31/07/2015 2015 EGM Chairman's Address 2
28/07/2015 ! Appendix 4C - quarterly 5
24/07/2015 Prima raises A$10m through Share Purchase Plan 2
13/07/2015 ! Response to ASX Aware Letter 6
10/07/2015 Share Purchase Plan Offer Documents 14
10/07/2015 Prima Newsletter 8
07/07/2015 ! Share Purchase Plan 3
07/07/2015 ! Positive scientific advice received from the EMA for IMP321 3
29/06/2015 Notice of Extraordinary General Meeting/Proxy Form 127
23/06/2015 Appendix 3B 13
12/06/2015 Cleansing Notice 1
12/06/2015 Prima to present at Bioshares Biotech Summit 2
11/06/2015 Prima receives research tax credit cash rebate in France 2
10/06/2015 Appendix 3B 13
05/06/2015 Appendix 3B 13
05/06/2015 Ceasing to be a substantial holder 2
04/06/2015 Prima to maintain NASDAQ listing 2
04/06/2015 Appendix 3B 13
03/06/2015 Ceasing to be a substantial holder - J.P. Morgan 5
03/06/2015 Becoming a substantial holder - J.P. Morgan 6
02/06/2015 Appendix 3B 13
02/06/2015 Change in substantial holding 3

SEC Filing

Date Filing Description Link
2017-03-17 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-085720 (34 Act) Size: 312 KB
2017-03-17 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-085720 (34 Act) Size: 312 KB
2017-03-15 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-082579 (34 Act) Size: 29 KB
2017-03-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-073501 (34 Act) Size: 1 MB
2017-03-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-066008 (34 Act) Size: 27 KB
2017-03-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-066008 (34 Act) Size: 27 KB
2017-02-24 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-056508 (34 Act) Size: 59 KB
2017-02-15 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-043852 (34 Act) Size: 56 KB
2017-02-15 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-043852 (34 Act) Size: 56 KB
2017-01-24 6-K PRIMA BIOMED TO PRESENT AT 2ND ANNUAL CANCER IMMUNOTHERAPY CONFERENCE - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-015477 (34 Act) Size: 59 KB
2017-01-24 CT ORDER Confidential treatment order Acc-no: 9999999997-17-000319 (34 Act) Size: 10 KB
2017-01-20 6-K PRIMA BIOMED COMMENCES RANDOMISED PHASE IIb CLINICAL TRIAL FOR IMP321 IN BREAST CANCER - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-013600 (34 Act) Size: 58 KBPRIMA BIOMED COMMENCES RANDOMISED PHASE IIb CLINICAL TRIAL FOR IMP321 IN BREAST CANCER
2017-01-18 6-K PRIMA BIOMED TO MAINTAIN NASDAQ LISTING - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-012453 (34 Act) Size: 56 KB
2017-01-12 6-K PRIMA BIOMED COMMENCES RECRUITMENT FOR SECOND COHORT OF MELANOMA TRIAL - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-008937 (34 Act) Size: 28 KB
2017-01-09 6-K Corporate Presentation - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-004696 (34 Act) Size: 7 MB
2017-01-06 6-K Appendix 4C - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-004638 (34 Act) Size: 117 KB
2017-01-05 6-K PRIMA BIOMED ENTERS NEW MATERIAL TRANSFER AGREEMENT WITH CYTLIMIC - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-003123 (34 Act) Size: 58 KB
2017-01-04 6-K Prima Announces New Product Candidate IMP761 – A LAG-3 Agonist Antibody – Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-17-000897 (34 Act) Size: 57 KB
2016-12-29 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-807452 (34 Act) Size: 55 KB
2016-12-22 6-K PRIMA BIOMED ANNOUNCES DATA FROM IMP321 AIPAC CLINICAL TRIAL IN BREAST CANCER - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-801097 (34 Act) Size: 57 KB
2016-12-21 6-K PRIMA BIOMED RECEIVES UK APPROVAL FOR AIPAC STUDY – Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-799105 (34 Act) Size: 55 KB
2016-12-20 6-K Prima BioMed Announces ADR Ratio Change - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-797546 (34 Act) Size: 59 KB
2016-12-07 6-K Change of Director’s Interest Notice - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-786804 (34 Act) Size: 244 KB
2016-12-07 6-K Appendix 3B - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-786804 (34 Act) Size: 244 KB
2016-12-01 6-K Appendix 3B - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-782708 (34 Act) Size: 182 KB
2016-11-28 6-K Results of Meeting - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-777623 (34 Act) Size: 5 MB
2016-11-28 6-K 2016 AGM CEO Presentation - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-777623 (34 Act) Size: 5 MB
2016-11-28 6-K 2016 AGM Address to Shareholders - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-777623 (34 Act) Size: 5 MB
2016-11-23 6-K Wuxi & Prima sign MOU for strategic partnership - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-776472 (34 Act) Size: 33 KB
2016-11-14 6-K Presentation slides for Society for Immunotherapy of Cancer - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-766853 (34 Act) Size: 1 MB
2016-11-14 6-K Investor Update - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-766851 (34 Act) Size: 2 MB
2016-10-27 6-K NOTICE OF 2016 ANNUAL GENERAL MEETING - Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-748126 (34 Act) Size: 249 KB
2016-10-21 6-K Appendix 4C – Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-742956 (34 Act) Size: 115 KB
2016-10-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-737209 (34 Act) Size: 31 KB
2016-10-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-732974 (34 Act) Size: 32 KB
2016-10-04 6-K Change of Director’s Interest Notice – Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-730618 (34 Act) Size: 293 KB
2016-10-04 6-K Appendix 3B & Cleansing Notice – Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-730618 (34 Act) Size: 293 KB
2016-10-03 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Acc-no: 0001193125-16-729297 (34 Act) Size: 2 MB
2016-09-29 6-K Annual Report – Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-725877 (34 Act) Size: 15 MB
2016-09-29 6-K Key to Disclosures Corporate Governance Council Principles and Recommendations – Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-725877 (34 Act) Size: 15 MB
2016-09-29 6-K CORPORATE GOVERNANCE STATEMENT – Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-725877 (34 Act) Size: 15 MB
2016-09-06 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-701115 (34 Act) Size: 229 KB
2016-09-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-698636 (34 Act) Size: 1 MB
2016-08-25 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-690463 (34 Act) Size: 59 KB
2016-08-18 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-685317 (34 Act) Size: 59 KB
2016-08-11 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-678252 (34 Act) Size: 60 KB
2016-07-28 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-660603 (34 Act) Size: 80 KB
2016-07-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-646565 (34 Act) Size: 34 KB
2016-06-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-629176 (34 Act) Size: 31 KB
2016-06-17 16:30:00 EFFECT Notice of Effectiveness Acc-no: 9999999995-16-004930 (33 Act) Size: 1 KB
2016-06-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-614568 (34 Act) Size: 57 KB
2016-05-27 F-3 Registration statement by foreign private issuers Acc-no: 0001193125-16-606353 (33 Act) Size: 364 KB
2016-05-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-606329 (34 Act) Size: 580 KB
2016-05-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-606329 (34 Act) Size: 580 KB
2016-05-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-606329 (34 Act) Size: 580 KB
2016-05-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-606329 (34 Act) Size: 580 KB
2016-05-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-589213 (34 Act) Size: 45 KB
2016-05-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-589207 (34 Act) Size: 617 KB
2016-05-03 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-573161 (34 Act) Size: 26 KB
2016-04-22 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-550664 (34 Act) Size: 101 KB
2016-04-11 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-535890 (34 Act) Size: 79 KB
2016-03-16 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-505506 (34 Act) Size: 30 KB
2016-03-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-496833 (34 Act) Size: 30 KB
2016-03-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-495408 (34 Act) Size: 208 KB
2016-03-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-492318 (34 Act) Size: 31 KB
2016-03-02 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-490040 (34 Act) Size: 46 KB
2016-03-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-485929 (34 Act) Size: 488 KB
2016-02-11 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-459656 (34 Act) Size: 331 KB
2016-02-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-444808 (34 Act) Size: 32 KB
2016-01-28 6-K Documents Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-440128 (34 Act) Size: 43 KB
2016-01-11 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-425954 (34 Act) Size: 57 KB
2016-01-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-16-423298 (34 Act) Size: 76 KB
2016-01-05 CT ORDER Confidential treatment order Acc-no: 9999999997-16-016146 (34 Act) Size: 13 KB
2015-12-29 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-416073 (34 Act) Size: 149 KB
2015-12-22 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-410722 (34 Act) Size: 74 KB
2015-12-11 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-400733 (34 Act) Size: 67 KB
2015-11-30 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-389727 (34 Act) Size: 57 KB
2015-11-25 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-388463 (34 Act) Size: 5 MB
2015-11-25 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-388463 (34 Act) Size: 5 MB
2015-11-24 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-386934 (34 Act) Size: 316 KB
2015-11-18 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-380213 (34 Act) Size: 45 KB
2015-11-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-368279 (34 Act) Size: 49 KB
2015-11-02 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-362102 (34 Act) Size: 38 KB
2015-10-30 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Acc-no: 0001193125-15-360683 (34 Act) Size: 3 MB
2015-10-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-354901 (34 Act) Size: 47 KB
2015-10-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-350961 (34 Act) Size: 14 MB
2015-10-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-350961 (34 Act) Size: 14 MB
2015-10-23 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-350961 (34 Act) Size: 14 MB
2015-10-20 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-347318 (34 Act) Size: 44 KB
2015-10-15 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-344237 (34 Act) Size: 41 KB
2015-10-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-342833 (34 Act) Size: 1 MB
2015-10-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-342833 (34 Act) Size: 1 MB
2015-10-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-341974 (34 Act) Size: 36 KB
2015-10-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-339788 (34 Act) Size: 665 KB
2015-10-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-336771 (34 Act) Size: 4 MB
2015-10-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-336771 (34 Act) Size: 4 MB
2015-10-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-336771 (34 Act) Size: 4 MB
2015-09-25 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-327868 (34 Act) Size: 36 KB
2015-08-31 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-307598 (34 Act) Size: 1 MB
2015-08-17 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-292742 (34 Act) Size: 41 KB
2015-08-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-277233 (34 Act) Size: 61 KB
2015-08-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-277201 (34 Act) Size: 481 KB
2015-08-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-277201 (34 Act) Size: 481 KB
2015-08-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-277201 (34 Act) Size: 481 KB
2015-08-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-277201 (34 Act) Size: 481 KB
2015-08-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-277201 (34 Act) Size: 481 KB
2015-08-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-277159 (34 Act) Size: 698 KB
2015-08-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-275186 (34 Act) Size: 41 KB
2015-08-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-275181 (34 Act) Size: 73 KB
2015-08-04 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-275181 (34 Act) Size: 73 KB
2015-07-30 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-271227 (34 Act) Size: 161 KB
2015-07-29 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-266602 (34 Act) Size: 113 KB
2015-07-27 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-263004 (34 Act) Size: 57 KB
2015-07-14 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-251470 (34 Act) Size: 35 KB
2015-07-13 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-250486 (34 Act) Size: 815 KB
2015-07-10 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-249572 (34 Act) Size: 3 MB
2015-07-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-246913 (34 Act) Size: 40 KB
2015-07-07 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-246005 (34 Act) Size: 46 KB
2015-07-06 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-244725 (34 Act) Size: 2 MB
2015-06-24 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-232155 (34 Act) Size: 158 KB
2015-06-15 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-223509 (34 Act) Size: 31 KB
2015-06-15 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-223504 (34 Act) Size: 42 KB
2015-06-11 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-219927 (34 Act) Size: 34 KB
2015-06-11 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-219577 (34 Act) Size: 139 KB
2015-06-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-216528 (34 Act) Size: 138 KB
2015-06-08 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-216518 (34 Act) Size: 32 KB
2015-06-05 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-214256 (34 Act) Size: 150 KB
2015-06-05 SC 13G Statement of acquisition of beneficial ownership by individuals Acc-no: 0000902664-15-002738 (34 Act) Size: 82 KB
2015-06-02 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-209979 (34 Act) Size: 150 KB
2015-06-01 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Acc-no: 0001193125-15-207931 (34 Act) Size: 144 KB

Financial Reports